On Monday, Indivior Pharmaceuticals (INDV) shares rose more than 3% on their final day as a standalone company, after its merger with Supernus Pharmaceuticals (SUPN) closed. The combined business describes itself as a leading diversified central nervous system (CNS) biopharmaceutical company and will operate under the Supernus name and ticker. Under the deal terms, Supernus shareholders receive just over 1.5 Indivior shares for each Supernus share they own, while Indivior shareholders receive a one-time special cash dividend of $1 billion before the merger closed. Indivior shareholders are expected to hold about 56.5% of the combined business, and the companies aim to reach $125 million in annual cost synergies.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
mergers and acquisitionspharmaceuticalsdividends
Open a keyword to see other news on the same topic.
Related news
- Great News for AbbVie Stock Investors
AbbVie (ABBV) shares have climbed 26% this year on strong financial performance, and the author sees a bright medium-term outlook. Skyrizi, the company's biggest growth driver, generated almost $10 billion in sales in the first half, up 27%, but its U.S. patents may begin expiring by 2033, potentially opening the door to cheaper biosimilars. On Oct. 19, AbbVie reported encouraging Phase 2a results for ABBV-466, which combines risankizumab and trosunilimab, though these must still be confirmed in Phase 3 studies. Its $10.9 billion cash acquisition of Apogee Therapeutics brought zumilokibart, which AbbVie hopes can challenge Dupixent (over $15 billion in annual sales), with maintenance injections possibly only every three or six months. Rinvoq should not face U.S. generics until 2037, and the author says AbbVie can deliver competitive long-term returns, with a forward yield of 2.5% versus the S&P 500's average of 1.1%.
- Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?
Merck (NYSE:MRK) closed at $145.45 on October 12. In the first quarter it booked an acquired research charge of roughly $9.00 billion tied to the Cidara acquisition, and a further charge for Terns in the second quarter. These went through R&D expense with no tax benefit, which pushes the operating margin below zero. The article argues they are one-time purchase-price write-offs rather than recurring cash costs, since free cash flow came in at several times net income, so the 266.67% payout ratio is distorted; revenue still grew 5.10% in the latest quarter. The bigger question is whether the well over ten billion dollars spent on pipeline assets that have yet to produce revenue can replace sales from its largest product once it loses exclusivity later this decade, with debt at $53.91 billion. The 15.62 forward multiple assumes that bet pays off.
- Company with female CEO born in 2002 issues important announcement
Ben Tre Pharmaceutical JSC (Bepharco, DBT) plans to issue more than 1.53 million shares to pay its 2025 dividend at a 7% ratio, with the final record date set for 16 November 2026. Shareholders holding 100 shares will receive 7 new shares, funded by undistributed after-tax profit as of 31 December 2025. If fully issued, charter capital would rise from nearly VND 219.7 billion to about VND 235 billion. Ms Nguyen Thuy Dung stepped down as chief accountant effective 2 November 2026, replaced by Mr Nguyen Nhat Phi for a term to 31 October 2027, and Ms Dung had registered to sell 14,687 DBT shares in October 2026. Tran Ngo Minh Anh, born in 2002 and daughter of Tran Ngo Phuc Vu, chairman of Nam A Bank, was appointed CEO from 1 November 2026, replacing Nguyen Khac Hanh, who resigned. In the first half of 2026, net revenue reached nearly VND 418 billion and after-tax profit nearly VND 25 billion, with DBT shares at VND 13,100 and a market cap of about VND 288 billion.
- Looking For Growth, Income, and Stability? This Stock Could Offer All 3
The article argues that Amgen combines growth, income and stability. In the second quarter, revenue rose 10% year over year to $10.1 billion, and 22 products posted at least double-digit sales growth despite the upcoming loss of patent exclusivity for denosumab. Newer therapies such as Tezspire, Tepezza and Imdelltra are driving growth, and MariTide, an investigational GLP-1 medicine in Phase 3 studies, could launch within a few years. The stock rose about 16% in 2022 when broader equities fell, and the dividend has grown 152% over the past decade. With a trailing-12-month cash payout ratio of 51.9% and a forward yield of 2.3% versus the S&P 500's average of 1.1%, the author considers Amgen suitable for income-focused investors.
- Is AbbVie a Buy After Its Latest Earnings Report?
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3% year over year, and adjusted EPS of $3.82, beating the midpoint of its guidance by about $0.07. Excluding costs tied to acquiring experimental drugs, adjusted EPS rose about 17%, from $3.36 to $3.93. Skyrizi and Rinvoq grew 22.7% and 23.9% and together made up 48.7% of revenue, while Humira sales fell to $683 million from $993 million. The company modestly raised full-year adjusted EPS guidance to $13.95 to $13.99 and increased its quarterly dividend 5.2% to $1.82, starting in February. The author remains bullish on AbbVie's long-term prospects but says its current valuation makes the 2027 guidance, due with fourth-quarter results, especially important.
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
Related markets
Latest news
- ELEKTROS (OTC:ELEK) Evaluates Northern New York Lithium Opportunity as U.S. Demand for Critical Minerals Takes Center Stage
ELEKTROS Inc. (OTC PINK: ELEK) is evaluating a potential hard-rock lithium opportunity in northern New York near the Canadian border, but the review is at an early exploratory stage, with no completed acquisition and no independently verified mineral resource or reserve. The article cites remarks by Elon Musk and President Donald Trump on the importance of lithium-ion batteries and critical minerals, but notes these statements do not refer to the property under review and do not indicate any government contract or endorsement. Further steps could include confirming ownership and mineral rights, obtaining independent geological analysis, reviewing environmental and permitting requirements, and assessing infrastructure and logistics. The company is also exploring development relationships for its multi-port EV charging patent, but treats this as a separate activity and has not announced a prototype, patent license, or revenue tied to it.
- Ternus touts Apple's $600B US manufacturing pledge on Q4 earnings call
Apple says its American manufacturing program is deepening partnerships with suppliers nationwide. Among them are Perimen, a titanium producer supplying the iPhone Duo, and Qunedy Electronics, which makes the camera technology behind the variable aperture system in the iPhone 18 Pro. Nearly 100 components in the company's newest iPhones come from American companies in more than a dozen states. Apple says it supports more than 450,000 American jobs through thousands of suppliers and partners across all 50 states, as part of its $600 billion four-year commitment to US innovation and advanced manufacturing.
- i-80 Gold Reports Third Quarter 2026 Results; Archimedes Underground on Track to Begin Production Mining by Year-End
i-80 Gold reported third-quarter 2026 revenue of $32.7 million from 7,744 ounces of gold sold at an average realized price of $4,211 per ounce, with production of 11,685 ounces, marginally lower than 12,428 ounces a year earlier. The net loss widened to $48.4 million from $41.9 million, mainly due to higher drilling costs at the Ruby Hill property, while gross profit rose to $5.0 million on a higher realized gold price. The Granite Creek underground project declared initial Mineral Reserves of 556,500 ounces of gold, and the Archimedes underground is on track to begin production mining before year-end 2026. The company targets annual gold production of 150,000 to 200,000 ounces in 2028 and 400,000 to 500,000 gold equivalent ounces in the early 2030s, with Mineral Point open pit now prioritized for a pre-feasibility study.
- Memory Headwinds Are 'Unprecedented'
Apple says memory-related headwinds will not go away anytime soon. The company expects them to keep weighing on its margins for the next several quarters.
- Stock Market Today, Nov. 2: Apple Stock Slides Ahead of Earnings, but Its Latest Results Tell a Different Story
Apple shares fell 1.83% to $338.32 on Monday amid a broader technology sell-off. After the close, Apple reported fiscal fourth-quarter earnings that beat expectations, with revenue of $114.5 billion and earnings of $2.10 per share, supported by strong demand for the iPhone 18. iPhone revenue rose about 17% year over year to $57.6 billion. However, gross margin fell to 47.9% from 50.1% in the previous quarter, reflecting higher component costs and a smaller benefit from tariff refunds, while sales in China and the iPad business fell short of expectations. The S&P 500 fell 0.50% to 7,542 and the Nasdaq Composite lost 1.07% to 25,164.
- AMD Reports Tuesday. Here's the Number That Will Show Whether It's Gaining on Nvidia
Advanced Micro Devices will report third-quarter results after the market closes Tuesday, after shares fell nearly 11% on Friday and declined again Monday amid broader chip stock weakness, leaving the stock nearly 30% below its all-time high reached less than a month earlier. AMD guided revenue of about $13 billion, plus or minus $300 million, while analysts expect $13.09 billion, up 41.5% from a year ago. The article points to fourth-quarter guidance, especially data center GPU contribution as Helios systems ramp, as the more important figure, with the average analyst estimate at about $16.3 billion and Jefferies' Blayne Curtis expecting closer to $17 billion. Compared with Nvidia's $89 billion of data center revenue last quarter, AMD's data center segment generated $6.7 billion, and the article flags risks including lower margins on AI chips and Intel's warning about a shrinking PC market.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.